Adarza BioSystems

Founded in 2008, Adarza has developed a highly sensitive label-free diagnostic platform capable of measuring 100s more individual proteins than the best multiplex immunoassays available today. The Arrayed Imaging Reflectometry (AIR™) is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid. Adarza delivers industry leading precision, accuracy, and robustness enabling highly multiplexed protein detection with high sensitivity and specificity. The company’s unique technology is flexible, data-rich, and easy to use, providing the only solution that spans the entire companion diagnostic life cycle from discovery to clinic, in both high-throughput core facilities as well as point of care (POC). Much like the first gene-chips enabled multiplexed genomics analysis, Adarza’s first-to-market high-multiplex and sensitivity antibody chips will fundamentally disrupt the field of proteomics research. Adarza is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at University of Rochester by Dr. Benjamin Miller, Adarza’s scientific founder.
West Henrietta, US
12 (est)+20%

Adarza BioSystems Locations

West Henrietta, US
Saint Peters, US

Adarza BioSystems Metrics

Adarza BioSystems Summary

Founding Date


Total Funding

$14.1 M

Latest funding size

$5 M

Time since last funding

7 months


Siemens Venture Capital, Cultivation Capital, St. Louis Arch Angels, Serra Ventures, BioGenerator, Siemens Venture Capital, Cultivation Capital, Lewis & Clark Ventures

Adarza BioSystems Company Life